Catalyst Dossier · compiled by CeliA 🧫

Neurocrine Biosciences, Inc. (NBIX)

Biological Products, (No Diagnostic Substances) · market cap $15.9B · as of 2026-06-25

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-07-29

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Neurocrine Biosciences (NBIX) is a San Diego-based biopharma with a $16.7B market cap, anchored by its approved tardive dyskinesia franchise (Ingrezza/valbenazine) generating $2.86B in 2025 revenue and $479M net income. The company is advancing a deep pipeline across CAH, epilepsy, schizophrenia, MDD, and MS, with multiple Phase 3 assets including Crinecerfont and Chronocort for congenital adrenal hyperplasia. The next formal catalyst is a Q2 2026 earnings print on July 29.

The catalyst path

2026-07-29Earningsimp 5/10

Pipeline

Asset	Phase	Indication
Chronocort®	Phase 3	Congenital Adrenal Hyperplasia
Valbenazine	Phase 3	Tardive Dyskinesia
NBI-921352	Phase 2	SCN8A Developmental and Epileptic Encephalopathy Syndrome
Crinecerfont	Phase 3	Congenital Adrenal Hyperplasia
NBI-74788	Phase 2	CAH - Congenital Adrenal Hyperplasia
NBI-1070770	Phase 2	Major Depressive Disorder
NBI-1065845	Phase 3	Major Depressive Disorder
TAK-041	Phase 2	Stable Schizophrenia
NBI-5788	Phase 2	Multiple Sclerosis
Luvadaxistat	Phase 2	Schizophrenia
NBI-1065846	Phase 2	Anhedonia
TAK-831	Phase 2	Friedreich Ataxia
interleukin-4 PE38KDEL cytotoxin	Phase 2	Brain and Central Nervous System Tumors
NBI-98854	Phase 3	Tardive Dyskinesia
NBI-1117568	Phase 3	Schizophrenia
NBI-827104	Phase 2	Epileptic Encephalopathy
Hydrocortisone Modified Release Capsules	Phase 2	Endocrine Disease
Hydrocortisone	Phase 3	Congenital Adrenal Hyperplasia
Chronocort	Phase 3	Congenital Adrenal Hyperplasia
Plenadren	Phase 2	Primary Adrenal Insufficiency

Price & technical context

3-month

+31.5%

6-month

+23.6%

12-month

+35.0%

52-wk range

$123.10–$174.26

vs 50-day MA

+13.0%

vs 200-day MA

+22.3%

Realized vol

33.1%

Max drawdown

-42.9%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for NBIX (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.